SCHEMBL1574518

SCHEMBL1574518

CCCN(CCC)C1CN(C(=O)Nc2ccccc2F)C1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.61
RAB9A P51151 4/20 0.47
NPC1 O15118 2/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
EPHX2 P34913 1/20 0.45
TP53 P04637 1/20 0.44
GAA P10253 2/20 0.43
FAAH O00519 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CASP3 P42574 1/20 0.41
MAPT P10636 1/20 0.41
GFER P55789 1/20 0.41
TRPV1 Q8NER1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574831 0.90 KDM4E (0.64) KDM4ERAB9ANPC1TAS1R3TAS1R1
SCHEMBL1575289 0.89 KDM4E (0.59) KDM4ERAB9ANPC1TAS1R3TAS1R1
SCHEMBL1575666 0.86 TAAR1 (0.52) KDM4ETAS1R3TAS1R1TP53KMT2A
SCHEMBL1574926 0.86 GAA (0.49) KDM4ERAB9ANPC1EPHX2GAA
SCHEMBL1574697 0.86 KDM4E (0.56) KDM4ERAB9ANPC1TAS1R3TAS1R1
SCHEMBL1575295 0.85 GAA (0.53) KDM4ETAS1R3TAS1R1EPHX2TP53
SCHEMBL1574941 0.84 KDM4E (0.60) KDM4ERAB9ANPC1TAS1R3TAS1R1
SCHEMBL1575080 0.83 KDM4E (0.58) KDM4EKMT2A
SCHEMBL1574472 0.82 ALDH1A1 (0.54) RAB9ANPC1GAASMN1; SMN2KMT2A
SCHEMBL1574781 0.82 GRIN2B (0.50) KDM4ERAB9ANPC1TP53FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB KDM4E 516/4885RAB9A 898/4885NPC1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.